1
|
Esteban F, Ramos-García P, Muñoz M, González-Moles MÁ. Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 19:ijerph19010375. [PMID: 35010633 PMCID: PMC8751191 DOI: 10.3390/ijerph19010375] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 12/26/2021] [Accepted: 12/27/2021] [Indexed: 05/09/2023]
Abstract
Head and neck cancer is a growing worldwide public health problem, accounting for approximately 1,500,000 new cases and 500,000 deaths annually. Substance P (SP) is a peptide of the tachykinin family, which has roles related to a large number of physiological mechanisms in humans. The implications of SP in carcinogenesis have recently been reported through the stimulation of the neurokinin 1 receptor (NK1R), or directly, through the effects derived from the constitutive activation of NK1R. Consequently, SP/NK1R seems to play relevant roles in cancer, upregulating cell proliferation, cell migration and chronic inflammation, among other oncogenic actions. Furthermore, there is growing evidence pointing to a central role for SP in tumour progression, singularly so in laryngeal and oral squamous cell carcinomas. The current narrative review of the literature focuses on the relationship between the SP/NK1R system and chronic inflammation and cancer in the head-and-neck region. We described a role for SP/NK1R in the transition from chronic inflammation of the head and neck mucosa, to preneoplastic and neoplastic transformation and progression.
Collapse
Affiliation(s)
- Francisco Esteban
- Department of Otolaryngology, Hospital Universitario Virgen del Rocío, University of Sevilla, 41004 Sevilla, Spain;
| | - Pablo Ramos-García
- School of Dentistry, University of Granada, 18010 Granada, Spain;
- Instituto de Investigación Biosanitaria ibs.Granada, 18012 Granada, Spain
- Correspondence:
| | - Miguel Muñoz
- Research Laboratory on Neuropeptides (IBIS), Virgen del Rocío University Hospital, 41013 Sevilla, Spain;
| | - Miguel Ángel González-Moles
- School of Dentistry, University of Granada, 18010 Granada, Spain;
- Instituto de Investigación Biosanitaria ibs.Granada, 18012 Granada, Spain
| |
Collapse
|
2
|
Massimino L, Lovisa S, Antonio Lamparelli L, Danese S, Ungaro F. Gut eukaryotic virome in colorectal carcinogenesis: Is that a trigger? Comput Struct Biotechnol J 2020; 19:16-28. [PMID: 33363706 PMCID: PMC7750180 DOI: 10.1016/j.csbj.2020.11.055] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 11/24/2020] [Accepted: 11/28/2020] [Indexed: 02/07/2023] Open
Abstract
The human gut microbiota is composed of bacteria and viruses that might be associated with colorectal cancer (CRC) onset and progression. Indeed, although viral infections have been reported to be the primary trigger in many diseases, the role of eukaryotic viruses populating the gut mucosa during early colorectal carcinogenesis is underinvestigated. Human eukaryotic viruses in the gut were found to induce alterations of the immune homeostasis so that some viral-dependent mechanisms likely able to induce DNA alterations in the bowel wall have been proposed, although no demonstration is available yet. However, thanks to the latest advancements in computational biology and the implementation of the bioinformatic pipelines, the option of establishing a direct causative link between intestinal virome and CRC will be possible soon, hopefully paving the way to innovative therapeutic strategies blocking or reverting the CRC pathogenesis.
Collapse
Affiliation(s)
- Luca Massimino
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - Sara Lovisa
- IBD Center, Laboratory of Gastrointestinal Immunopathology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | | | - Silvio Danese
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
- IBD Center, Laboratory of Gastrointestinal Immunopathology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - Federica Ungaro
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
- IBD Center, Laboratory of Gastrointestinal Immunopathology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| |
Collapse
|
3
|
Survey of Impediments to Prevention of Mother-to-infant Transmission of Hepatitis B Virus by International Societies. J Pediatr Gastroenterol Nutr 2019; 69:648-654. [PMID: 31503215 DOI: 10.1097/mpg.0000000000002483] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
OBJECTIVE Mother-to-infant transmission (MIT) is the leading cause of hepatitis B virus (HBV) infections globally. The aim of this international study was to assess the impediments to prevention of (MIT) of HBV. METHODS A cross-sectional survey was developed by the Federation of the International Societies for Pediatric Gastroenterology, Hepatology and Nutrition. (FISPGHAN) The survey was sent to HBV experts of the 5-member societies of FISPGHAN, and 63 of 91 countries/regions responded. Main outcome measures include percentage of countries having vaccine programs, timing of the first dose of HBV vaccine, availability of HBV vaccine for outborn neonates, payment of HBV vaccine and hepatitis B immune globulin, screening HBV markers during pregnancy, and antivirals to highly infectious pregnant mothers. RESULTS Among the participating countries/regions, 11% did not implement infant HBV immunization programs. The first dose of vaccine was given >24 hours in 36% of the total countries and 100% of African countries. The recommended birth dose was unavailable for outborn neonates in 45% of the total countries, including 92% of African and 50% of Latin American countries/regions. During pregnancy, 44% countries do not screen maternal viral markers, and 46% do not provide third trimester antiviral therapy for highly viremic pregnant mothers. CONCLUSIONS Our study demonstrated multiple obstacles to achieving the goal of preventing MIT of HBV. Comprehensive public health programs to enhance vaccine coverage rate, supply HBV vaccine for out-born neonates, screening maternal HBV markers, treating highly viremic pregnant mothers are proposed to overcome these obstacles and achieve the goal of preventing MIT of HBV.
Collapse
|
4
|
Cryo-EM structure of native spherical subviral particles isolated from HBV carriers. Virus Res 2018; 259:90-96. [PMID: 30391399 DOI: 10.1016/j.virusres.2018.10.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2018] [Revised: 10/19/2018] [Accepted: 10/19/2018] [Indexed: 11/24/2022]
Abstract
Hepatitis B virus (HBV) contains 3 types of particles, i.e., 22-nm-diameter spherical and tubular subviral particles (SVPs) and 44-nm-diameter Dane particles. The SVPs are non-infectious and present strong immunogenicity, while Dane particles are infectious. In this study, we isolated spherical SVPs from HBV carriers' sera and determined their 3D structure at the resolution of ∼30 Å by cryo-electron microscopy (cryo-EM) single-particle reconstruction. Our cryo-EM structure suggests that the native HBV spherical SVP is irregularly organized, where spike-like features are arranged in a crystalline-like pattern on the surface. Strikingly, the hepatitis B surface antigen (HBsAg) in the native spherical SVPs folds as protrusions on the surface, as those on the native tubular SVPs and Dane particles, but is largely different from that in the recombinant octahedral SVPs. These results suggest a universal folding shape of HBsAg on the native HBV viral and subviral particles.
Collapse
|
5
|
Hosseini SN, Ghaisari P, Sharifnia S, Khatami M, Javidanbardan A. Improving the recovery of clarification process of recombinant hepatitis B surface antigen in large-scale by optimizing adsorption-desorption parameters on Aerosil-380. Prep Biochem Biotechnol 2018; 48:490-497. [DOI: 10.1080/10826068.2018.1466153] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
| | - Parisa Ghaisari
- Department of Chemical Engineering, Razi University, Kermanshah, Iran
| | - Shahram Sharifnia
- Department of Chemical Engineering, Razi University, Kermanshah, Iran
| | - Maryam Khatami
- Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran
| | - Amin Javidanbardan
- Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
6
|
Abstract
In this review, we address selected areas that are central to the state-of-the-art of cancer prevention science. The emphasis on prevention as a viable and critical approach to decreasing cancer mortality has gained traction in recent years, evidenced by its inclusion in the US Vice President's Cancer Initiative (also termed 'Moonshot'). Cancer prevention occurs by arresting, slowing down, or reversing the carcinogenic process before invasion into surrounding tissue or by avoiding or blocking causative exposure. An important challenge is to identify individuals who will benefit most from preventive interventions with the least possible harm. Preventive interventions range from avoiding known carcinogens (e.g., tobacco or asbestos) to intervening with anticarcinogenic strategies (behavioral modifications , such as diet and exercise; medications; nutritional agents; and vaccination against causative agents). Here, we focus on active intervention with measures involving pharmaceutical and immunological agents.
Collapse
Affiliation(s)
- Barbara K Dunn
- National Cancer Institute, Division of Cancer Prevention, 9609 Medical Center Drive, MSC 9787, Bethesda, MD 20892-9787, USA
| | - Barnett S Kramer
- National Cancer Institute, Division of Cancer Prevention, 9609 Medical Center Drive, MSC 9787, Bethesda, MD 20892-9787, USA
| |
Collapse
|
7
|
Van Den Ende C, Marano C, Van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines 2017; 16:811-832. [DOI: 10.1080/14760584.2017.1338568] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
| | | | - Ayla Van Ahee
- Pallas Health Research and Consultancy, Rotterdam, The Netherlands
| | - Eveline M. Bunge
- Pallas Health Research and Consultancy, Rotterdam, The Netherlands
| | | |
Collapse
|
8
|
Widespread geographical disparities in chronic hepatitis B virus infection in Algeria. Arch Virol 2017; 162:1641-1648. [PMID: 28236070 DOI: 10.1007/s00705-017-3284-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2016] [Accepted: 02/07/2017] [Indexed: 12/11/2022]
Abstract
Algeria is the largest country of Africa, with a population of 40 million inhabitants living in disparate environments from the Sahara to the large cities of the Mediterranean coast. The molecular epidemiology of hepatitis B virus (HBV) variants has been partially described, but variations in the seroprevalence of HBV surface antigen (HBsAg) throughout the Algerian territories are still poorly described. We analyzed demographic features of new cases of chronic infection collected in 41 administrative regions (covering 92% of the population) in 2013. The mean age of the 1876 HBsAg(+) patients was 36.8 ± 14.2 years, with a slight excess of males (54%). The seroprevalence of HBV early antigen (HBeAg) was 9.3%, and the mean virus load was 3.2 ± 1.8 log IU/ml. A subset of 15.2% of patients was already cirrhotic at disease discovery. An important heterogeneity was observed throughout the country, with nine regions displaying a significant excess of cases. These regions formed four distinct foci located in distant parts of the country: Adrar-Bechar (southwest), El-Oued-Tebessa (east), M'Sila-Sétif (north central) and Oran-Aïn Temouchent (northwest). An excess of cases was found as well in the national capital Algiers. Patients from southern regions with an excess of cases (Bechar, Adrar, El Oued) were significantly younger (32.0 ± 10.7 years), as were patients from the regions of Bejaia and Bouira (32.1 ± 10.6). The southwestern regions were also marked by a significant imbalance of the sex ratio (58 vs 39% of female cases, P = 4.5 E-5). The highest HBeAg seroprevalence was observed in Setif (26.4 vs. 7.6%, OR = 4.3, 95% CI 2.6-6.5, P = 1.1 × 10-11) in accordance with the higher virus loads observed in the patients (3.9 ± 2.3 vs. 3.1 ± 1.6, P = 0.0002). In conclusion, we observed heterogeneity in HBsAg seroprevalence, demographic traits, and disease evolution in Algeria. Further studies are now warranted to shed light on these differences, which are presumably due to variability in transmission routes or in the infectivity of viral isolates.
Collapse
|
9
|
Li J, Ge J, Ren S, Zhou T, Sun Y, Sun H, Gu Y, Huang H, Xu Z, Chen X, Xu X, Zhuang X, Song C, Jia F, Xu A, Yin X, Du SX. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection. Vaccine 2015; 33:4247-54. [PMID: 25858855 DOI: 10.1016/j.vaccine.2015.03.079] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Revised: 03/16/2015] [Accepted: 03/24/2015] [Indexed: 12/12/2022]
Abstract
Hepatitis B virus infection is a non-cytopathic hepatotropic virus which can lead to chronic liver disease and hepatocellular carcinoma. Traditional therapies fail to provide sustained control of viral replication and liver damage in most patients. As an alternative strategy, immunotherapeutic approaches have shown promising efficacy in the treatment of chronic hepatitis B patients. Here, we investigated the efficacy of a novel therapeutic vaccine formulation consisting of two HBV antigens, HBsAg and HBcAg, and CpG adjuvant. This vaccine formulation elicits forceful humoral responses directed against HBsAg/HBcAg, and promotes a Th1/Th2 balance response against HBsAg and a Th1-biased response against HBcAg in both C57BL/6 and HBV transgenic mice. Vigorous cellular immune response was also detected in HBV transgenic mice, for a significantly higher number of HBs/HBc-specific IFN-γ secreting CD4+ and CD8+ T cells was generated. Moreover, vaccinated mice elicited significantly intense in vivo CTL attack, reduced serum HBsAg level without causing liver damage in HBV transgenic mice. In summary, this study demonstrates a novel therapeutic vaccine with the potential to elicit vigorous humoral and cellular response, overcoming tolerance in HBV transgenic mice.
Collapse
Affiliation(s)
- Jianqiang Li
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China.
| | - Jun Ge
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Sulin Ren
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Tong Zhou
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Ying Sun
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Honglin Sun
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Yue Gu
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Hongying Huang
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Zhenxing Xu
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Xiaoxiao Chen
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China
| | - Xiaowei Xu
- Jiangsu Theravac Bio-pharmaceutical CO., Ltd, Nanjing 210042, China; State Key Laboratory of Nature Medicines, China Pharmaceutical University, Nanjing 210009, China
| | - Xiaoqian Zhuang
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Nanjing 210042, China
| | - Cuiling Song
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Nanjing 210042, China
| | - Fangmiao Jia
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Nanjing 210042, China
| | - Aiguo Xu
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Nanjing 210042, China
| | - Xiaojin Yin
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Nanjing 210042, China
| | - Sean X Du
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Nanjing 210042, China
| |
Collapse
|
10
|
Wang T, Zhen Y, Ma X, Wei B, Li S, Wang N. Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain. Colloids Surf B Biointerfaces 2015; 126:520-30. [PMID: 25612819 DOI: 10.1016/j.colsurfb.2015.01.005] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2014] [Revised: 12/11/2014] [Accepted: 01/04/2015] [Indexed: 10/24/2022]
Abstract
To develop an effective, convenient and stable mucosal vaccine against hepatitis B virus (HBV), the mannose-PEG-cholesterol/lipid A-liposomes (MLLs) loaded with HBsAg were prepared by the procedure of emulsification-lyophilization and, subsequently, filled into the microholes of microneedle array reverse molds and dried to form the proHBsAg-MLLs microneedle arrays (proHMAs). The proHMAs were stable even at 40 °C for up to 3 days and hard enough to pierce porcine skin but, upon rehydration, rapidly dissolved recovering the HBsAg-MLLs without obvious changes in size and antigen association efficiency. Notably, immunization of mice only once with the proHMAs at oral mucosa induced robust systemic and widespread mucosal immunoresponses, as evidenced by the high levels of HBsAg-specific IgG in the sera and IgA in the salivary, intestinal and vaginal secretions. In addition, a strong cellular immunity against HBV had been established through a mixed Th1/Th2 response, as confirmed by a significant increase in CD8(+) T cells as well as the enhanced levels of IgG2a and IFN-γ in the treated mice. Thus, the proHMAs can be conveniently vaccinated via oral mucosal route to set up a multiple immune defense against HBV invasion and, in addition, may be a stable HBV vaccine applicable in the controlled temperature chain for wide distribution.
Collapse
Affiliation(s)
- Ting Wang
- School of Pharmacy, Anhui Medical University, 81 Plum Hill Road, Hefei, Anhui Province 230032, China.
| | - Yuanyuan Zhen
- School of Pharmacy, Anhui Medical University, 81 Plum Hill Road, Hefei, Anhui Province 230032, China
| | - Xiaoyu Ma
- School of Pharmacy, Anhui Medical University, 81 Plum Hill Road, Hefei, Anhui Province 230032, China
| | - Biao Wei
- School of Pharmacy, Anhui Medical University, 81 Plum Hill Road, Hefei, Anhui Province 230032, China
| | - Shuqin Li
- School of Pharmacy, Anhui Medical University, 81 Plum Hill Road, Hefei, Anhui Province 230032, China
| | - Ning Wang
- School of Medical Engineering, Hefei University of Technology, 193 Tunxi Road, Hefei, Anhui Province 230009, China.
| |
Collapse
|
11
|
Shrestha B, Rath JP. Poly(vinyl alcohol)‐coated chitosan microparticles act as an effective oral vaccine delivery system for hepatitis B vaccine in rat model. IET Nanobiotechnol 2014; 8:201-7. [DOI: 10.1049/iet-nbt.2013.0035] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Bijaya Shrestha
- Department of Medical BiotechnologyChettinad Hospital and Research InstituteChettinad Academy of Research and EducationKelambakkam, ChennaiTamil Nadu 603103India
| | - Jyoti Prakash Rath
- Department of Medical BiotechnologyChettinad Hospital and Research InstituteChettinad Academy of Research and EducationKelambakkam, ChennaiTamil Nadu 603103India
- Department of ChemistryGangadhar Meher CollegeSambalpur768004OdishaIndia
| |
Collapse
|
12
|
Changes of costimulatory molecule CD28 on circulating CD8+ T cells correlate with disease pathogenesis of chronic hepatitis B. BIOMED RESEARCH INTERNATIONAL 2014; 2014:423181. [PMID: 25013781 PMCID: PMC4071789 DOI: 10.1155/2014/423181] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Revised: 05/09/2014] [Accepted: 05/18/2014] [Indexed: 01/29/2023]
Abstract
Costimulatory signals are critical for antiviral immunity. The aim of this study was to evaluate the change of costimulatory molecule CD28 on circulating CD8+ T cells in chronic hepatitis B patients (CHB). Seventy CHB patients and fifty-six healthy controls were included, and forty-eight CHB patients were recruited for 52 weeks of longitudinal investigation. The proportions of circulating CD8+CD28+ and CD8+CD28− subpopulations were determined by flow cytometry, and the CD8+CD28+/CD8+CD28− T cells ratio was calculated. Compared with the subpopulation in healthy controls, high proportions of CD8+CD28− subpopulation were observed in CHB patients. Similarly, the CD8+CD28+/CD8+CD28− T cells ratio was significantly decreased in CHB patients compared with healthy controls and correlated significantly with hepatitis B virus (HBV) loads. High proportions of CD8+CD28− subpopulation and low CD8+CD28+/CD8+CD28− T cells ratio were observed in hepatitis B e antigen- (HBeAg-) positive individuals as compared with that in HBeAg-negative subjects. A significant decrease in CD8+CD28− subpopulation, increase in CD8+CD28+ subpopulation, and CD8+CD28+/CD8+CD28− T cells ratio were seen in those patients who received efficient antiviral therapy. Thus, aberrant CD28 expression on circulating CD8+ T cells and the CD8+CD28+/CD8+CD28− T cells ratio reflect the dysregulation of T cell activation and are related to the pathogenesis of chronic HBV infection.
Collapse
|
13
|
Zhu Y, Zhang T, Zhao J, Weng Z, Yuan Q, Li S, Zhang J, Xia N, Zhao Q. Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen. Hum Vaccin Immunother 2014; 10:1013-23. [PMID: 24499806 DOI: 10.4161/hv.27753] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Prophylactic vaccines against hepatitis B Virus (HBV) infection were produced in different expression systems under different processing conditions. Since the recombinant HBV surface antigen (HBsAg) in these vaccines is a cysteine-rich protein with 14 cysteines among a total of 226 amino acids, the epitopes are dependent on the formation of intra- and intermolecular disulfide bonds. A panel of 22 monoclonal antibodies (mAbs) were developed and evaluated with respect to their sensitivity to disulfide reduction treatment of recombinant HBsAg. Not surprisingly, different mAbs showed different degree of sensitivity to controlled HBsAg disulfide reduction. With a view to exploring the functionality of anti-HBsAg mAbs to be used in HBsAg quality analysis, in vitro neutralization activity for the mAbs was assessed. One of the mAbs tested, 5F11, which showed high sensitivity to the disulfide integrity in HBsAg, was shown also to be highly effective in neutralizing HBV in vitro. Conversely, 42B6, while exhibiting similar neutralization activity, showed comparable binding HBsAg with or without reduction treatment. Based on these mAb characteristics, a sandwich ELISA with 42B6 being the capture Ab and detection Ab was developed to quantify HBsAg (like a "mass" assay) during antigen bioprocessing or in vaccine products. In parallel, when 5F11 was used as the detection Ab (with the same capture Ab), the assay can be used to probe disulfide-dependent and virion-like epitopes in intermediates or final products of hepatitis B vaccine, serving as a surrogate marker for vaccine efficacy to elicit neutralizing antibodies. This approach enables the comparative epitope specific antigenicity analysis of HBsAg antigen preparations from different sources.
Collapse
Affiliation(s)
- Yibin Zhu
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Life Sciences; Xiamen University; Xiamen, Fujian, PR China
| | - Tianying Zhang
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Life Sciences; Xiamen University; Xiamen, Fujian, PR China
| | - Jinghua Zhao
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Life Sciences; Xiamen University; Xiamen, Fujian, PR China
| | - Zusen Weng
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Life Sciences; Xiamen University; Xiamen, Fujian, PR China
| | - Quan Yuan
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Public Health; Xiamen University; Xiamen, Fujian, PR China
| | - Shaowei Li
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Life Sciences; Xiamen University; Xiamen, Fujian, PR China; School of Public Health; Xiamen University; Xiamen, Fujian, PR China
| | - Jun Zhang
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Public Health; Xiamen University; Xiamen, Fujian, PR China
| | - Ningshao Xia
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Life Sciences; Xiamen University; Xiamen, Fujian, PR China; School of Public Health; Xiamen University; Xiamen, Fujian, PR China
| | - Qinjian Zhao
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University; Xiamen, Fujian, PR China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; Xiamen University; Xiamen, Fujian, PR China; School of Public Health; Xiamen University; Xiamen, Fujian, PR China
| |
Collapse
|
14
|
Hao C, Wang J, Kang W, Xie Y, Zhou Y, Ma L, Peng M, Bai X, Lian J, Jia Z. Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B. Viral Immunol 2013; 26:336-42. [PMID: 24028690 DOI: 10.1089/vim.2013.0032] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Th17 cells and the secreting cytokines play an important role in the immune response and inflammation that is induced by hepatitis B virus (HBV). However, it remains not fully elucidated how the antiviral agents affect Th17 cytokines and signal pathway. Telbivudine therapy has been proved to inhibit HBV replication effectively and to improve clinical outcome of chronic hepatitis B (CHB). Thus, in this study, the effect of decrease in viral load and liver dysfunction resulting from telbivudine treatment on Th17 cells and the related cytokines IL-17, IL-22, and IL-23 were analyzed. Peripheral blood mononuclear cells and serum from twenty-four CHB patients were harvested at 0, 12, 24, 36, and 48 weeks after initiation of telbivudine treatment. In parallel to the reduction of HBV DNA and normalization of serum ALT, significant declines in circulating HBV-specific Th17 cells and IL-22 production were found during antiviral therapy. The expression of serum IL-22 and IL-23, but not IL-17 also decreased during therapy. Our findings suggest that antiviral effect of telbivudine may attribute to both direct virus inhibition and regulation of inflammation, which further improve the understanding of pathogenesis of HBV infection and develop antiviral strategy for controlling viral hepatitis.
Collapse
Affiliation(s)
- Chunqiu Hao
- Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University , Xi'an, Shannxi Province, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31:1197-203. [DOI: 10.1016/j.vaccine.2012.12.074] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Revised: 12/13/2012] [Accepted: 12/23/2012] [Indexed: 12/14/2022]
|
16
|
The twenty-year story of a plant-based vaccine against hepatitis B: stagnation or promising prospects? Int J Mol Sci 2013; 14:1978-98. [PMID: 23337199 PMCID: PMC3565360 DOI: 10.3390/ijms14011978] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Revised: 01/07/2013] [Accepted: 01/14/2013] [Indexed: 01/20/2023] Open
Abstract
Hepatitis B persists as a common human disease despite effective vaccines having been employed for almost 30 years. Plants were considered as alternative sources of vaccines, to be mainly orally administered. Despite 20-year attempts, no real anti-HBV plant-based vaccine has been developed. Immunization trials, based on ingestion of raw plant tissue and conjugated with injection or exclusively oral administration of lyophilized tissue, were either impractical or insufficient due to oral tolerance acquisition. Plant-produced purified HBV antigens were highly immunogenic when injected, but their yields were initially insufficient for practical purposes. However, knowledge and technology have progressed, hence new plant-derived anti-HBV vaccines can be proposed today. All HBV antigens can be efficiently produced in stable or transient expression systems. Processing of injection vaccines has been developed and needs only to be successfully completed. Purified antigens can be used for injection in an equivalent manner to the present commercial vaccines. Although oral vaccines require improvement, plant tissue, lyophilized or extracted and converted into tablets, etc., may serve as a boosting vaccine. Preliminary data indicate also that both vaccines can be combined in an effective parenteral-oral immunization procedure. A partial substitution of injection vaccines with oral formulations still offers good prospects for economically viable and efficacious anti-HBV plant-based vaccines.
Collapse
|
17
|
Chen Y, Qiu LM, Yao XS, Zhuang QJ, Lv H. Effect of antiviral treatment with nucleoside and nucleotide analogues on cellular immune function in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2012; 20:3521-3528. [DOI: 10.11569/wcjd.v20.i35.3521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
China is a country where hepatitis B virus (HBV) infection is highly endemic, and a large sample survey shows that chronic HBV infection affects as many as 120 million people in China. Since immune response dysregulation caused by persistent HBV infection and replication is the underlying cause of disease progression in patients with chronic hepatitis B (CHB), effective antiviral therapy should be given to halt the progression of the disease. Nucleoside and nucleotide analogues have been generally accepted as effective anti-HBV drugs and widely used in the clinical setting. They exert antiviral effects against HBV mainly by inhibition of DNA polymerase-mediated DNA replication. In addition, nucleoside and nucleotide analogues also have an impact on the body's immune function. In this article we review recent progress in understanding the effect of antiviral treatment with nucleoside and nucleotide analogues on cellular immune function in CHB patients.
Collapse
|
18
|
Vaccinology: the name, the concept, the adjectives. Vaccine 2012; 30:5491-5. [PMID: 22766245 DOI: 10.1016/j.vaccine.2012.06.059] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Revised: 06/17/2012] [Accepted: 06/18/2012] [Indexed: 02/04/2023]
Abstract
The visibility of the term vaccinology has become more pronounced in the 21st century in defining a scientific field that has absorbed aspects from different scientific domains until finally acquiring an identity of its own. As a result, vaccinology brings together a long tradition of researchers who have operated within a linear paradigm and incorporates new generations of scientists who have forged an exciting and diverse network of knowledge within this field. The term vaccinology, which initially appeared in isolation at the time of Jenner and once again with the emergence of the Pasteurian model, acquired further prominence thanks to the efforts of the vaccinologists who chronicled the production of vaccines in the last third of the 20th century. The term has since become truly consolidated, with the appearance of new adjectives during this century. This study provides a historical perspective for the frequency of use and evolution of this increasingly widespread term.
Collapse
|
19
|
Cancer therapy and vaccination. J Immunol Methods 2012; 382:1-23. [PMID: 22658969 DOI: 10.1016/j.jim.2012.05.014] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2011] [Revised: 04/01/2012] [Accepted: 05/24/2012] [Indexed: 12/18/2022]
Abstract
Cancer remains one of the leading causes of death worldwide, both in developed and in developing nations. It may affect people at all ages, even fetuses, but the risk for most varieties increases with age. Current therapeutic approaches which include surgery, chemotherapy and radiotherapy are associated with adverse side effects arising from lack of specificity for tumors. The goal of any therapeutic strategy is to impact on the target tumor cells with limited detrimental effect to normal cell function. Immunotherapy is cancer specific and can target the disease with minimal impact on normal tissues. Cancer vaccines are capable of generating an active tumor-specific immune response and serve as an ideal treatment due to their specificity for tumor cells and long lasting immunological memory that may safeguard against recurrences. Cancer vaccines are designed to either prevent (prophylactic) or treat established cancer (therapeutic). Identification of tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) has led to increased efforts to develop vaccination strategies. Vaccines may be composed of whole cells or cell extracts, genetically modified tumor cells to express costimulatory molecules, dendritic cells (DCs) loaded with TAAs, immunization with soluble proteins or synthetic peptides, recombinant viruses or bacteria encoding tumor-associated antigens, and plasmid DNA encoding TSAs or TAAs in conjunction with appropriate immunomodulators. All of these antitumor vaccination approaches aim to induce specific immunological responses and localized to TAAs, destroying tumor cells alone and leaving the vast majority of other healthy cells of the body untouched.
Collapse
|
20
|
Kutscher S, Bauer T, Dembek C, Sprinzl M, Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol 2012; 5:270-82. [PMID: 21958338 PMCID: PMC3815787 DOI: 10.1111/j.1751-7915.2011.00303.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2011] [Revised: 08/22/2011] [Accepted: 08/22/2011] [Indexed: 12/18/2022] Open
Abstract
Therapeutic vaccines are currently developed for chronic viral infections, such as human papillomavirus (HPV), human immunodeficiency virus (HIV), herpesvirus and hepatitis B (HBV) and C (HCV) virus infections. As an alternative to antiviral treatment or to support only partially effective therapy a therapeutic vaccine shall activate the patient's immune system to fight and finally control or ideally even eliminate the virus. Whereas the success of prophylactic vaccination is based on rapid neutralization of the invading pathogen by antibodies, virus control and elimination of infected cells require T cells. Therefore, induction of a multi-specific and multifunctional T-cell response against key viral antigens is a paradigm of therapeutic vaccination--besides activation of a humoral immune response to limit virus spread. In this review, we describe options to develop a therapeutic vaccine for chronic viral infections using HBV as a promising example.
Collapse
Affiliation(s)
| | | | | | | | - Ulrike Protzer
- Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Trogerstr. 30, 81675 München, Germany
| |
Collapse
|
21
|
Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X. Nanobodies®: New ammunition to battle viruses. Antiviral Res 2011; 92:389-407. [DOI: 10.1016/j.antiviral.2011.09.002] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2011] [Revised: 08/30/2011] [Accepted: 09/06/2011] [Indexed: 01/23/2023]
|
22
|
Sogut I, Hatipoglu I, Kanbak G, Basalp A. Monoclonal Antibodies Specific for Hepatitis B e Antigen and Hepatitis B Core Antigen. Hybridoma (Larchmt) 2011; 30:475-9. [DOI: 10.1089/hyb.2011.0052] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Ibrahim Sogut
- Genetic Engineering and Biotechnology Institute, Tubitak Marmara Research Center, Gebze–Kocaeli, Turkey
- Department of Biochemistry, Eskisehir Osmangazi University, Eskisehir, Turkey
| | - Ibrahim Hatipoglu
- Genetic Engineering and Biotechnology Institute, Tubitak Marmara Research Center, Gebze–Kocaeli, Turkey
| | - Gungor Kanbak
- Department of Biochemistry, Eskisehir Osmangazi University, Eskisehir, Turkey
| | - Aynur Basalp
- Genetic Engineering and Biotechnology Institute, Tubitak Marmara Research Center, Gebze–Kocaeli, Turkey
| |
Collapse
|
23
|
Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. Biochem Biophys Res Commun 2011; 408:447-53. [PMID: 21527246 DOI: 10.1016/j.bbrc.2011.04.048] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2011] [Accepted: 04/11/2011] [Indexed: 11/22/2022]
Abstract
The Hepatitis B virus major surface antigen (HBsAg) is a cysteine-rich, membrane-bound protein which self-assembles into 22-nm spherical virus-like particles (VLPs). While this VLP based human vaccine has been demonstrated to be safe and efficacious since 1986, the structural and exact molecular basis for its antigenic determinants has not been elucidated. Maturation of the yeast-derived purified VLPs was characterized for the changes in 37 their biophysical properties. Using rapid and label-free surface plasmon resonance technique with a neutralizing monoclonal antibody - A1.2, the epitope evolution kinetics of purified VLPs was monitored in real time. Evidence supporting the mechanism that the correct disulfide bond pairing is the molecular basis for shaping up the native virion-like epitopes was obtained. At least 10-fold enhancement in antigenicity probed by A1.2 of the VLPs was achieved by heat-treatment (t(1/2) ∼ 6-10 h), and another 2- to 3-fold enhancement was obtained when they were treated with redox buffer. This antigenicity development, presumably via disulfide formation/isomerization, was shown to be inhibited by a free radical scavenger and facilitated in the presence of light. Relative antigenicity determination with surface plasmon resonance was shown to be a valuable tool for process characterization in the kinetic monitoring mode or for final VLP product assessment in the end point antigenicity testing mode.
Collapse
|
24
|
Saini V, Jain V, Sudheesh M, Jaganathan K, Murthy P, Kohli D. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. Int J Pharm 2011; 408:50-7. [DOI: 10.1016/j.ijpharm.2011.01.045] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2010] [Revised: 01/21/2011] [Accepted: 01/24/2011] [Indexed: 11/26/2022]
|
25
|
Cavenaugh JS, Awi D, Mendy M, Hill AVS, Whittle H, McConkey SJ. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One 2011; 6:e14626. [PMID: 21347224 PMCID: PMC3039644 DOI: 10.1371/journal.pone.0014626] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2008] [Accepted: 11/25/2010] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secondary goal was to characterize the immune responses. METHODS Firstly 32 HBV e antigen negative (eAg(-)) participants were randomly assigned to one of four groups: to receive vaccines alone, lamivudine (3TC) alone, both, or neither. Later 16 eAg(+) volunteers in two groups received either 3TC alone or both 3TC and vaccines. Finally, 12 eAg(-) and 12 eAg(+) subjects were enrolled into higher-dose treatment groups. Healthy but chronically HBV-infected males between the ages of 15-25 who lived in the western part of The Gambia were eligible. Participants in some groups received 1 mg or 2 mg of pSG2.HBs intramuscularly twice followed by 5×10(7) pfu or 1.5×10(8) pfu of MVA.HBs intradermally at 3-weekly intervals with or without concomitant 3TC for 11-14 weeks. Intradermal rabies vaccine was administered to a negative control group. Safety was assessed clinically and biochemically. The primary measure of efficacy was a quantitative PCR assay of plasma HBV. Immunity was assessed by IFN-γ ELISpot and intracellular cytokine staining. RESULTS Mild local and systemic adverse events were observed following the vaccines. A small shiny scar was observed in some cases after MVA.HBs. There were no significant changes in AST or ALT. HBeAg was lost in one participant in the higher-dose group. As expected, the 3TC therapy reduced viraemia levels during therapy, but the prime-boost vaccine regimen did not reduce the viraemia. The immune responses were variable. The majority of IFN-γ was made by antigen non-specific CD16(+) cells (both CD3(+) and CD3(-)). CONCLUSIONS The vaccines were well tolerated but did not control HBV infection. TRIAL REGISTRATION ISRCTN ISRCTN67270384.
Collapse
Affiliation(s)
- James S. Cavenaugh
- Medical Research Council Laboratories, Banjul,
The Gambia
- Centre for Clinical Vaccinology and Tropical
Medicine, University of Oxford, Oxford, United Kingdom
- David H. Smith Center for Vaccine Biology and
Immunology, School of Medicine and Dentistry, University of Rochester,
Rochester, New York, United States of America
| | - Dorka Awi
- Medical Research Council Laboratories, Banjul,
The Gambia
- Institute of Maternal and Child Health,
University of Port Harcourt, Post Harcourt, Nigeria
| | - Maimuna Mendy
- Medical Research Council Laboratories, Banjul,
The Gambia
- International Agency for Research on Cancer,
Lyon, France
| | - Adrian V. S. Hill
- Centre for Clinical Vaccinology and Tropical
Medicine, University of Oxford, Oxford, United Kingdom
- The Wellcome Trust Centre for Human Genetics,
Oxford, United Kingdom
| | - Hilton Whittle
- Medical Research Council Laboratories, Banjul,
The Gambia
| | - Samuel J. McConkey
- Medical Research Council Laboratories, Banjul,
The Gambia
- Centre for Clinical Vaccinology and Tropical
Medicine, University of Oxford, Oxford, United Kingdom
- Department of International Health and
Tropical Medicine, Royal College of Surgeons in Ireland, Dublin,
Ireland
| |
Collapse
|
26
|
|
27
|
Advances in effective vaccine development against hepatitis B: focus on mucosal vaccine delivery strategies. Ther Deliv 2010; 1:397-410. [DOI: 10.4155/tde.10.19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Hepatitis B virus causes chronic necroinflammatory liver disease, which is known as hepatitis B. This inflammatory condition may further aggravate liver cirrhosis or hepatocellular carcinoma. Currently available conventional hepatitis B vaccine contains one of the viral envelope proteins, hepatitis B surface antigen, which develops a humoral immune response and hence protects against the infection. However, it fails in developing the desired cellular immune response, which is one of the most important bioresponses contributing to virus elimination from infected hepatocytes. At the same time, moderate humoral response developed following conventional vaccination do not protect the mucosal surfaces through serosal response. The mucosa is a predominant entry site for most of the infectious pathogens. Several strategies, including the use of adjuvants, development of surface functionalized novel antigen carriers and mucosal immunization for example, have been explored to investigate their role in addressing the limitations associated with the current hepatitis B vaccine. This review focuses on recent advances that have been made in order to develop an effective vaccine against hepatitis B.
Collapse
|
28
|
Tomar P, Karwasara VS, Dixit VK. Development characterizations and evaluation of Poly(-ϵ-caprolactone)-based microspheres for hepatitis B surface antigen delivery. Pharm Dev Technol 2010; 16:489-96. [DOI: 10.3109/10837450.2010.492220] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
29
|
Bergonzini V, Salata C, Calistri A, Parolin C, Palù G. View and review on viral oncology research. Infect Agent Cancer 2010; 5:11. [PMID: 20497566 PMCID: PMC2881002 DOI: 10.1186/1750-9378-5-11] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Accepted: 05/24/2010] [Indexed: 01/05/2023] Open
Abstract
To date, almost one and a half million cases of cancer are diagnosed every year in the US and nearly 560,000 Americans are expected to die of cancer in the current year, more than 1,500 people a day (data from the American Cancer Society at http://www.cancer.org/). According to the World Health Organization (WHO), roughly 20% of all cancers worldwide results from chronic infections; in particular, up to 15% of human cancers is characterized by a viral aetiology with higher incidence in Developing Countries. The link between viruses and cancer was one of the pivotal discoveries in cancer research during the past Century. Indeed, the infectious nature of specific tumors has important implications in terms of their prevention, diagnosis, and therapy. In the 21st Century, the research on viral oncology field continues to be vigorous, with new significant and original studies on viral oncogenesis and translational research from basic virology to treatment of cancer. This review will cover different viral oncology aspects, starting from the history of viral oncology and moving to the peculiar features of oncogenic RNA and DNA viruses, with a special focus on human pathogens.
Collapse
Affiliation(s)
- Valeria Bergonzini
- Department of Histology, Microbiology and Medical Biotechnologies, Division of Microbiology and Virology, University of Padova, Via A Gabelli 63, Padova 35121, Italy
| | - Cristiano Salata
- Department of Histology, Microbiology and Medical Biotechnologies, Division of Microbiology and Virology, University of Padova, Via A Gabelli 63, Padova 35121, Italy
| | - Arianna Calistri
- Department of Histology, Microbiology and Medical Biotechnologies, Division of Microbiology and Virology, University of Padova, Via A Gabelli 63, Padova 35121, Italy
| | - Cristina Parolin
- Department of Biology, University of Padova, Via Ugo Bassi 58B, Padova 35123, Italy
| | - Giorgio Palù
- Department of Histology, Microbiology and Medical Biotechnologies, Division of Microbiology and Virology, University of Padova, Via A Gabelli 63, Padova 35121, Italy
| |
Collapse
|
30
|
Lin C, Zhu J, Zheng Y, Chen Y, Wu Z, Chong Y, Gao Z. Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders. J Infect 2010; 60:264-70. [PMID: 20138189 DOI: 10.1016/j.jinf.2010.01.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2009] [Revised: 01/07/2010] [Accepted: 01/31/2010] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To assess the immune effects and safety of using GM-CSF with the yeast-recombinant hepatitis B virus (HBV) vaccine for the re-vaccination of healthy adults who did not respond to a previous vaccination. METHODS Study participants included 1784 healthy adults and 100 individuals diagnosed as non-responders. These healthy non-responders were randomly assigned to one of the three treatment groups: Group A (34 individuals) was given 150 microg of granulocyte-macrophage colony stimulating factor (GM-CSF) the first day, then 20 microg of the vaccine; Group B (33 individuals) was given 40 microg of the vaccine only; and, group C (33 individuals) was injected with 20 microg of vaccine each time. All participants were injected three times, at time of study enrollment and one and six months later. Anti-HB surface antigen (HBs) antibody titers were tested before treatment and at one (T1), two (T2) and eight (T8) months post-first injection. RESULTS At T1, the rate of anti-HBs antibody(+) in groups A, B and C was 26.47%, 48.48% and 18.18%, respectively (p = .027). At T8, the seropositive rate of group A (64.71%) and group B (75.76%) was significantly higher than in group C (39.39%) (p = .011); the geometric mean of the antibody titer for groups A and B was higher than for group C (p = .0173). All three treatments were safe and well-tolerated. CONCLUSIONS Augmentation of the vaccine dose and co-administration of GM-CSF and the standard vaccine dose are effective for HBV vaccine non-responders. In fact, changing the vaccine dose had a better seropositive response than injecting the vaccine in combination with GM-CSF.
Collapse
Affiliation(s)
- Chaoshuang Lin
- Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Tianhe Road No. 600, Guangzhou 510630, China
| | | | | | | | | | | | | |
Collapse
|
31
|
Salem ML, El-Demellawy M, El-Azm ARA. The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Cell Immunol 2010; 262:96-104. [PMID: 20338549 DOI: 10.1016/j.cellimm.2010.03.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2010] [Accepted: 03/02/2010] [Indexed: 02/07/2023]
Abstract
Hepatitis C virus (HCV) infection is a major public health concern with approximately 3% of the world's population is infected, posing social, economical and health burden. Less than 20% of the infected individuals clear the virus during the acute infection, while the rest develop chronic infection. The treatment of choice for HCV infection is pegylated interferon-alpha (IFN-alpha) in combination with ribavarin. Despite the cost and side effects of this treatment regimen, many patients fail this therapy and develop persistent HCV infection, leading to cirrhosis and hepatocellular carcinoma. Although the mechanisms underlying the failure to resolve HCV infection are poorly understood, the incapability of patients to develop effective anti-HCV immunity is a potential cause. We hypothesize that the dysfunctional anti-HCV immunity is due to the emergence of immunosuppressive cells coinciding with a decrease in the stimulatory dendritic cells (DCs) and natural killer (NK) cells. We further hypothesize that applying agents that can correct the imbalance between the immunosuppressive cells and stimulatory cells can results in resolution of chronic HCV. In this review article, we will discuss potential approaches, focusing on the use of Toll-like receptor agonists, to block the suppressive effects of the regulatory cells and restore the stimulatory effects of DCs and NK cells.
Collapse
MESH Headings
- Adjuvants, Immunologic/therapeutic use
- Antiviral Agents/therapeutic use
- Dendritic Cells/immunology
- Enzyme Inhibitors/therapeutic use
- Hepacivirus/immunology
- Hepatitis C, Chronic/drug therapy
- Hepatitis C, Chronic/epidemiology
- Hepatitis C, Chronic/immunology
- Hepatitis C, Chronic/virology
- Humans
- Immunity, Innate
- Indoleamine-Pyrrole 2,3,-Dioxygenase/antagonists & inhibitors
- Interferon-alpha/therapeutic use
- Killer Cells, Natural/immunology
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Ribavirin/therapeutic use
- T-Lymphocytes, Regulatory/immunology
- Toll-Like Receptors/agonists
- Toll-Like Receptors/immunology
Collapse
Affiliation(s)
- Mohamed L Salem
- Surgery Department and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
| | | | | |
Collapse
|
32
|
Saini V, Jain V, Sudheesh MS, Dixit S, Gaur RL, Sahoo MK, Joseph SK, Verma SK, Jaganathan KS, Murthy PK, Kohli D. Humoral and cell-mediated immune-responses after administration of a single-shot recombinant hepatitis B surface antigen vaccine formulated with cationic poly(l-lactide) microspheres. J Drug Target 2009; 18:212-22. [DOI: 10.3109/10611860903386920] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
33
|
Shukla A, Katare OP, Singh B, Vyas SP. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm 2009; 385:47-52. [PMID: 19835938 DOI: 10.1016/j.ijpharm.2009.10.027] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2009] [Revised: 10/08/2009] [Accepted: 10/08/2009] [Indexed: 10/20/2022]
Abstract
The present study aims to improve upon our earlier findings with bilosomes as potential delivery vehicle through oral route for recombinant hepatitis B surface antigen (HBsAg). The work entails the conjugation of bilosomal system with cholera toxin B subunit (CTB) to increase transmucosal uptake via M-cell specific delivery approach. The study encompasses the development and characterization of HBsAg-loaded CTB-conjugated system for percent antigen entrapment, size, shape, and stability in SGF (USP, pH 1.2), SIF (USP, pH 7.5) and in bile salt solutions. Biological activity of CTB, subsequent to conjugation, was verified by hemagglutination test. Anti-HBsAg IgG response in serum and anti-HBsAg sIgA in various body secretions were estimated using ELISA, following oral immunization with 10 microg dose-loaded CTB-conjugated bilosomes (CTB2) and 20 microg dose-loaded CTB-conjugated bilosomes (CTB1) in BALB/c mice. The results showed that CTB1 produced anti-HBsAg IgG antibody titre response comparable to that of the intramuscular (i.m.) injection of 10 microg of alum-adsorbed HBsAg. Moreover, all the bilosomal preparations elicited measurable sIgA vis-à-vis negligible response with i.m. administered HBsAg. Thus, HBsAg-loaded CTB-conjugated bilosomes provide a promising potential for targeted oral immunization against hepatitis B.
Collapse
Affiliation(s)
- Anshuman Shukla
- Drug Delivery Research Group, University Institute of Pharmaceutical Sciences-UGC Centre of Advanced Studies, Panjab University, Chandigarh 160014, India
| | | | | | | |
Collapse
|
34
|
Akbar SMF, Hiasa Y, Mishiro S, Onji M. Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother 2009; 10:1605-14. [PMID: 19496738 DOI: 10.1517/14656560903005579] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND The treatment of individuals infected with hepatitis B virus (HBV) is a complex issue in practical settings, despite the explosion of new and effective antiviral agents. OBJECTIVE To assess the scope and limitations of ongoing treatment guidelines against HBV from a global perspective. METHODS Present therapeutic guidelines against HBV have been discussed with emphasis on their value in developing countries that harbor about 90% of the total number of global patients who are infected with HBV. RESULTS/CONCLUSION Treatment of HBV-infected patients should be appropriately followed up and healthcare delivery systems should be able to combat treatment-induced adverse side effects. Current therapeutic guidelines should be optimized based on the socio-economic conditions of developing countries.
Collapse
Affiliation(s)
- Sheikh Mohammad Fazle Akbar
- Department of Medical Sciences, Toshiba General Hospital, 6-3-22 Higashi Oi, Shinagawa, Tokyo 140-8522, Japan.
| | | | | | | |
Collapse
|
35
|
Barboza L, Salmen S, Peterson DL, Montes H, Colmenares M, Hernández M, Berrueta-Carrillo LE, Berrueta L. Altered T cell costimulation during chronic hepatitis B infection. Cell Immunol 2009; 257:61-8. [PMID: 19345343 DOI: 10.1016/j.cellimm.2009.02.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2008] [Revised: 12/16/2008] [Accepted: 02/26/2009] [Indexed: 01/12/2023]
Abstract
T-cell response to hepatitis B virus (HBV) is vigorous, polyclonal and multi-specific in patients with acute hepatitis who ultimately clear the virus, whereas it is narrow and inefficient in patients with chronic disease, where inappropriate early activation events could account for viral persistence. We investigated the induction of activation receptors and cytokine production in response to HBcAg and crosslinking of CD28 molecules, in CD4+ cells from a group of chronically infected patients (CIP) and naturally immune subjects (NIS). We demonstrated that CD4+ cells from CIP did not increase levels of CD40L and CD69 following stimulation with HBcAg alone or associated to CD28 crosslinking, in contrast to subjects that resolved the infection (p<0.01). Furthermore, CD4+ cells from CIP produced elevated levels of IL-10 in response to HBcAg. These results suggest that a predominant inhibitory environment may be responsible for altered T cell costimulation, representing a pathogenic mechanism for viral persistence.
Collapse
Affiliation(s)
- Luisa Barboza
- Institute of Clinical Immunology, University of Los Andes, Mérida-Venezuela
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Saini V, Sahoo M, Murthy P, Kohli D. Polymeric lamellar substrate particles as carrier adjuvant for recombinant hepatitis B surface antigen vaccine. Vaccine 2009; 27:2372-8. [DOI: 10.1016/j.vaccine.2009.02.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2008] [Revised: 02/01/2009] [Accepted: 02/05/2009] [Indexed: 11/25/2022]
|
37
|
Gurramkonda C, Adnan A, Gäbel T, Lünsdorf H, Ross A, Nemani SK, Swaminathan S, Khanna N, Rinas U. Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen. Microb Cell Fact 2009; 8:13. [PMID: 19208244 PMCID: PMC2646686 DOI: 10.1186/1475-2859-8-13] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2008] [Accepted: 02/10/2009] [Indexed: 11/18/2022] Open
Abstract
Background Hepatitis B is a serious global public health concern. Though a safe and efficacious recombinant vaccine is available, its use in several resource-poor countries is limited by cost. We have investigated the production of Hepatitis B virus surface antigen (HBsAg) using the yeast Pichia pastoris GS115 by inserting the HBsAg gene into the alcohol oxidase 1 locus. Results Large-scale production was optimized by developing a simple fed-batch process leading to enhanced product titers. Cells were first grown rapidly to high-cell density in a batch process using a simple defined medium with low salt and high glycerol concentrations. Induction of recombinant product synthesis was carried out using rather drastic conditions, namely through the addition of methanol to a final concentration of 6 g L-1. This methanol concentration was kept constant for the remainder of the cultivation through continuous methanol feeding based on the on-line signal of a flame ionization detector employed as methanol analyzer in the off-gas stream. Using this robust feeding protocol, maximum concentrations of ~7 grams HBsAg per liter culture broth were obtained. The amount of soluble HBsAg, competent for assembly into characteristic virus-like particles (VLPs), an attribute critical to its immunogenicity and efficacy as a hepatitis B vaccine, reached 2.3 grams per liter of culture broth. Conclusion In comparison to the highest yields reported so far, our simple cultivation process resulted in an ~7 fold enhancement in total HBsAg production with more than 30% of soluble protein competent for assembly into VLPs. This work opens up the possibility of significantly reducing the cost of vaccine production with implications for expanding hepatitis B vaccination in resource-poor countries.
Collapse
|
38
|
Serruys B, Van Houtte F, Verbrugghe P, Leroux-Roels G, Vanlandschoot P. Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepatology 2009; 49:39-49. [PMID: 19085971 DOI: 10.1002/hep.22609] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
UNLABELLED Hepatitis B virus (HBV) infections cause 500,000 to 700,000 deaths per year as a consequence of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Efficient and safe antivirals to treat chronically infected patients and consequently to prevent development of hepatocellular carcinoma are still awaited. We isolated five single-domain antibodies (VHHs) that recognize the most abundant envelope protein (S) of HBV. VHHs, when expressed and retained in the endoplasmic reticulum as intrabodies, reduced levels of secreted hepatitis B surface antigen (HBsAg) particles in a cellular HBV model. In a hydrodynamics-based HBV mouse model, these intrabodies caused a marked reduction in HBsAg concentrations and a 10- to >100-fold reduction in the concentration of HBV virions in plasma. CONCLUSION VHHs potently inhibited secretion of HBV virions in vivo, showing that this approach might be useful in the treatment of HBV. To our knowledge, this is the first report of intrabody-mediated inhibition of viral secretion in mammals.
Collapse
Affiliation(s)
- Benedikte Serruys
- Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
| | | | | | | | | |
Collapse
|
39
|
Chen Y, Chen HT, Wu SP, Yue HK, Ma Y, Fang AP. Effects of adefovir dipivoxil on the function of dendritic cells from chronic HBV-infected patients in vitro. Shijie Huaren Xiaohua Zazhi 2008; 16:3759-3764. [DOI: 10.11569/wcjd.v16.i33.3759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To find out effects of adefovir dipivoxil (ADV) on the function of dendritic cells (DCs) from peripheral blood of chronic HBV-infected patients in vitro.
METHODS: Monocytes (Mo) were purified from peripheral blood of healthy volunteers and HBV-infected patients with incubation of granulocyte/macrophage colony stimulating factor (GM-CSF), interleukin-4 (IL-4) and ADV at different concentrations (20, 100, 500 µg/L) added on day 6. DC's morphology was observed under inverted microscopy and the expressions of CD1a, CD83, CD86 and MHC-DR on DCs were analyzed using FACS. The ability to stimulate the proliferation of allogenic T cells by DCs was detected using methyl thiazolyl tetrazolium (MTT). The levels of IL-12 p40+p70 in culture supernatant of DCs were determined using ELISA.
RESULTS: Compared with HBV-infected patient group, a better differentiation of DCs, enhanced proliferation of allogenic T cells and increased secretion of IL-12 p40+p70 were observed in ADV treatment group. The DCs with 100 µg/L ADV had the highest expression of CD1a, CD83, CD86 and MHC-DR, significantly higher than those of DCs without ADV treatment (43.5 ± 5.7 vs 20.6 ± 2.8, 34.6 ± 1.9 vs 16.7 ± 3.4, 40.9 ± 2.8 vs 25.8 ± 6.6, 66.9 ± 5.4 vs 40.7 ± 4.2, all P < 0.05), but all lower than the healthy controls. Differences among the three groups were statistically significant (P < 0.05).
CONCLUSION: ADV enhances the immune ability of DCs from peripheral blood of HBV-infected patients, suggesting that ADV possibly participates in the immune response through modulation of function of DCs and plays an indirect antivirus role.
Collapse
|
40
|
Abstract
In the century since its inception, the field of tumor virology has provided groundbreaking insights into the causes of human cancer. Peyton Rous founded this scientific field in 1911 by discovering an avian virus that induced tumors in chickens; however, it took 40 years for the scientific community to comprehend the effect of this seminal finding. Later identification of mammalian tumor viruses in the 1930s by Richard Shope and John Bittner, and in the 1950s by Ludwik Gross, sparked the first intense interest in tumor virology by suggesting the possibility of a similar causal role for viruses in human cancers. This change in attitude opened the door in the 1960s and 1970s for the discovery of the first human tumor viruses--EBV, hepatitis B virus, and the papillomaviruses. Such knowledge proved instrumental to the development of the first cancer vaccines against cancers having an infectious etiology. Tumor virologists additionally recognized that viruses could serve as powerful discovery tools, leading to revolutionary breakthroughs in the 1970s and 1980s that included the concept of the oncogene, the identification of the p53 tumor suppressor, and the function of the retinoblastoma tumor suppressor. The subsequent availability of more advanced molecular technologies paved the way in the 1980s and 1990s for the identification of additional human tumor viruses--human T-cell leukemia virus type 1, hepatitis C virus, and Kaposi's sarcoma virus. In fact, current estimates suggest that viruses are involved in 15% to 20% of human cancers worldwide. Thus, viruses not only have been shown to represent etiologic agents for many human cancers but have also served as tools to reveal mechanisms that are involved in all human malignancies. This rich history promises that tumor virology will continue to contribute to our understanding of cancer and to the development of new therapeutic and preventive measures for this disease in the 21st century.
Collapse
Affiliation(s)
- Ronald T Javier
- Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA.
| | | |
Collapse
|
41
|
Lu GF, Tang FA, Zheng PY, Yang PC, Qi YM. Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B. World J Gastroenterol 2008; 14:1617-21. [PMID: 18330958 PMCID: PMC2693762 DOI: 10.3748/wjg.14.1617] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2007] [Revised: 01/25/2008] [Indexed: 02/06/2023] Open
Abstract
AIM To investigate the in vitro effect of entecavir (ETV) on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients. METHODS Mononuclear cells were isolated from peripheral blood of patients with CHB. DCs were incubated with RPMI-1640 medium supplemented with fetal bovine serum, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF). DCs were treated with or without ETV on the fourth day. Cell surface molecules, including CD1a, CD80, CD83 and HLA-DR, were assessed by flow cytometry. Concentrations of IL-6 and IL-12 in the supernatant were assayed by enzyme-linked immunosorbent assay (ELISA). The ability of the generated DCs to stimulate lymphocyte proliferation was observed. RESULTS Compared with CHB control group, the expression levels of CD1a (29.07 +/- 3.20 vs 26.85 +/- 2.80), CD83 (25.66 +/- 3.19 vs 23.21 +/- 3.10), CD80 (28.00 +/- 2.76 vs 25.75 +/- 2.51) and HLA-DR (41.96 +/- 3.81 vs 32.20 +/- 3.04) in ETV-treated group were higher (P < 0.05). ETV-treated group secreted significantly more IL-12 (157.60 +/- 26.85 pg/mL vs 132.60 +/- 22.00 pg/mL (P < 0.05) and had a lower level of IL-6 in the culture supernatant (83.05 +/- 13.88 pg/mL vs 93.60 +/- 13.61 pg/mL, P < 0.05) than CHB control group. The ability of DCs to stimulate the proliferation of allogeneic lymphocytes was increased in ETV-treated group compared with CHB control group (1.53 +/- 0.09 vs 1.42 +/- 0.08, P < 0.05). CONCLUSION Entecavir can enhance the biological activity of DCs derived from CHB patients.
Collapse
|
42
|
Dikici B, Dagli A, Ucmak H, Bilici M, Ece A. Efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infection. Pediatr Int 2007; 49:603-7. [PMID: 17875084 DOI: 10.1111/j.1442-200x.2007.02419.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND The purpose of the present paper was to investigate the efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B virus (CHB) infection. METHODS Fifty-eight immunotolerant children were prospectively and randomly recruited into two groups. Group 1 (study group) included 30 patients who received vitamin E at a dose of 100 mg/day throughout 3 months; group 2 (control group) contained 28 patients who did not receive any medication. Comparison of serological, virologic, and biochemical response ratios were done at the end of the therapy and after 6 months of vitamin E discontinuation. RESULTS Mean alanine transaminase (ALT) values in group 1 at the beginning of the therapy, 3 months after the therapy initiation and 6 months after discontinuation were 30.4 +/- 7.3 IU/L, 31.3 +/- 7.8 IU/L and 32.1 +/- 8.5 IU/L, respectively. The mean hepatitis B virus (HBV)-DNA load of group 1 at onset, and at the third and ninth months of the treatment were 3106 +/- 718 pg/mL, 3530 +/- 137 pg/mL and 3364 +/- 1246 pg/mL, respectively. These changes in both ALT and HBV-DNA values did not reach significant levels (P > 0.05). In group 2, mean ALT values at the beginning of therapy, and at the third and ninth months were 28.0 +/- 1.8 IU/L, 34.6 +/- 8.1 IU/L, and 34.1 +/- 7.0 IU/L, respectively (P > 0.05), and mean viral load of HBV-DNA was 4227 +/- 1435 pg/mL, 3368 +/- 2673 pg/mL, and 3018 +/- 2814 pg/mL, respectively (P > 0.05). There was no statistically significant difference between group 1 and group 2 at the third and ninth months in the mean ALT values and viral load of HBV-DNA (P > 0.05). Hepatitis B s antigen and hepatitis B e antigen clearance or hepatitis B s antibody and hepatitis B e antibody seroconversion were not observed in either group. CONCLUSION As a first study investigating the effect of vitamin E in children with immunotolerant CHB infection, no beneficial effect could be demonstrated. Different immunomodulator protocols should be considered for future investigations.
Collapse
Affiliation(s)
- Bunyamin Dikici
- Department of Pediatrics, Abant Izzet Baysal University, Duzce Medical Faculty, Duzce, Turkey.
| | | | | | | | | |
Collapse
|
43
|
Zheng PY, Zhang DY, Lu GF, Yang PC, Qi YM, Wang BS. Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection. World J Gastroenterol 2007; 13:4641-5. [PMID: 17729422 PMCID: PMC4611843 DOI: 10.3748/wjg.v13.i34.4641] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate if the nucleoside analogue lamivudine (LAM), a potent inhibitor of HBV replication, could restore the function of dendritic cells derived from patients with chronic hepatitis B (CHB) in an Asian population.
METHODS: Dendritic cells (DCs) derived from mononuclearcytes of patients with chronic HBV infection were cultured in the presence of IL-4, granulocyte-macrophage colony-stimulating factors (GM-CSF) and gradient concentrations of LAM (0-2 mmol/L). Cell morphology was observed under light microscopy. Cell surface molecules, including HLA-DR, CD80, CD83, and CD1α, were analyzed with flow cytometry. The concentrations of IL-6 and IL-12 in the supernatant were assayed by ELISA. T cell proliferation was assayed by methyl thiazolyl tetrazolium (MTT).
RESULTS: The expression of CD1α on DC treated with 0.5 mmol/L LAM (LAM-DC 0.5 mmol/L) was significantly higher than that of DC untreated with LAM (54.1 ± 4.21 vs 33.57 ± 3.14, P < 0.05), and so was the expression of CD83 (20.24 ± 2.51 vs 12.83 ± 2.12, P < 0.05) as well as the expression of HLA-DR (74.5 ± 5.16 vs 52.8 ± 2.51, P < 0.05). Compared with control group, LAM-DC group (0.5 mmol/L) secreted significantly more IL-12 (910 ± 91.5 vs 268 ± 34.3 pg/mL, P < 0.05), had lower levels of IL-6 in the culture supernatant (28 ± 2.6 vs 55 ± 7.36 pg/mL, P < 0.05), markedly enhanced the stimulatory capacity in the allogeneic mixed leukocyte reaction (MLR) (1.87 ± 0.6 vs 1.24 ± 0.51, P < 0.05).
CONCLUSION: The lower expression of phenotypic molecules and impaired allogeneic mixed lymphocyte reaction function of dendritic cells derived from patients with HBV infection could be restored in vitro by incubation with LAM.
Collapse
Affiliation(s)
- Peng-Yuan Zheng
- Department of Gastroenterology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
| | | | | | | | | | | |
Collapse
|
44
|
Abstract
Aptamers are rare nucleic acid ligands, which can be concocted in the laboratory from the randomized pool of molecules by affinity and amplification processes. Aptamers have several properties as they can be applied complementarily to antibodies and have several advantages over antibodies. In the past, several aptamers have been selected with a view to develop antiviral agents for therapeutic applications. This review summarizes potent antiviral aptamers and their strategies to prevent the viral replication.
Collapse
Affiliation(s)
- S C B Gopinath
- Functional Nucleic Acids Group, Institute for Biological Resources and Functions and Center for Applied Near Field Optics Research, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan.
| |
Collapse
|
45
|
Barboza L, Salmen S, Goncalves L, Colmenares M, Peterson D, Montes H, Cartagirone R, Gutiérrez MDC, Berrueta L. Antigen-induced regulatory T cells in HBV chronically infected patients. Virology 2007; 368:41-9. [PMID: 17643462 DOI: 10.1016/j.virol.2007.06.030] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2007] [Revised: 04/18/2007] [Accepted: 06/28/2007] [Indexed: 02/06/2023]
Abstract
T cell response against HBV is vigorous in patients with acute hepatitis who clear the virus, whereas it is weak and narrowly focused in patients with chronic disease. We report that following incubation with HBcAg, a population of CD4+FoxP3+ cells expressing phenotypic markers of both natural and induced Tregs, can be antigen-induced from peripheral mononuclear cells. Conversely, naive and naturally immune subjects did not increase CD4+FoxP3+ Tregs following stimulation with HBcAg, supporting the idea that natural Tregs are able to respond specifically to HBV antigen. Furthermore, increased frequencies of antigen-induced CD4+FoxP3+IL-10+ Tregs correlated with viral load, suggesting that antigen-induced Tregs could contribute to an inadequate response against the virus, leading to chronic infection and support the view that specific natural Tregs may be implicated in host immune tolerance during HBV infection.
Collapse
Affiliation(s)
- Luisa Barboza
- Institute of Clinical Immunology, University of Los Andes, Avenida 16 de Septiembre, Edificio Louis Pasteur, Anexo HULA, PO BOX 566, Mérida 5101, Venezuela
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Fazle Akbar SM, Furukawa S, Yoshida O, Hiasa Y, Horiike N, Onji M. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol 2007; 47:60-6. [PMID: 17467112 DOI: 10.1016/j.jhep.2007.02.021] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2006] [Revised: 02/11/2007] [Accepted: 02/27/2007] [Indexed: 01/30/2023]
Abstract
BACKGROUND/AIMS Antigen-pulsed dendritic cells (DCs) are now used for treatment of patients with cancers, however, the efficacy of these DCs has never been evaluated for prophylactic purposes. The aim of this study was (1) to prepare hepatitis B surface antigen (HBsAg)-pulsed human blood DCs, (2) to assess immunogenicity of HBsAg-pulsed DCs in vitro and (3) to evaluate the efficacy of HBsAg-pulsed DCs in hepatitis B (HB) vaccine nonresponders. METHODS Human peripheral blood DCs were cultured with HBsAg to prepare HBsAg-pulsed DCs. The expression of immunogenic epitopes of HBsAg on HBsAg-pulsed DCs was assessed in vitro. Finally, HBsAg-pulsed DCs were administered, intradermally to six HB vaccine nonresponders and the levels of antibody to HBsAg (anti-HBs) in the sera were assessed. RESULTS HB vaccine nonresponders did not exhibit features of immediate, early or delayed adverse reactions due to administration of HBsAg-pulsed DCs. Anti-HBs were detected in the sera of all HB vaccine nonresponders within 28 days after administration of HBsAg-pulsed DCs. CONCLUSIONS This study opens a new field of application of antigen-pulsed DCs for prophylactic purposes when adequate levels of protective antibody cannot be induced by traditional vaccination approaches.
Collapse
Affiliation(s)
- Sk Md Fazle Akbar
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Ehime 791-0295, Japan.
| | | | | | | | | | | |
Collapse
|
47
|
Lu GF, Tang FA, Zheng PY, Ma J, Bai JX. In vitro effect of entecavir on the function of dendritic cells derived from chronic hepatitis B patients. Shijie Huaren Xiaohua Zazhi 2007; 15:1292-1296. [DOI: 10.11569/wcjd.v15.i11.1292] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the effect of entecavir (ETV) on the function of dendritic cells (DC) derived from patients with chronic hepatitis B (CHB) in vitro.
METHODS: Peripheral blood mononuclear cells were isolated from CHB patients and healthy controls. After proliferation under induction, the cells were cultured by routine method. Then ETV was added to co-incubate with the cells on the 4th day. On day 8, DC were collected for the detection of phenotypes and mixed lymphocytic reactions.
RESULTS: After 8 d of cultivation, the differentiation of DC in the healthy controls was better than that in ETV-treated group, while ETV-treated group had a better differentiation than CHB group. In comparison with those in the healthy controls, the levels of CD1a (35.73 ± 3.12 vs 62.31 ± 5.22), CD80 (28.19 ± 1.64 vs 45.38 ± 3.10), CD83 (22.24 ± 2.14 vs 40.63 ± 7.21) and HLA-DR (36.74 ± 0.98 vs 56.05 ± 3.89) expression were significantly decreased in CHB group (all P < 0.01). However, the levels of CD83 (27.41 ± 9.23 vs 22.24 ± 2.14, P < 0.05), CD80 (32.67 ± 7.82 vs 28.19 ± 1.64, P < 0.05) and HLA-DR (40.84 ± 5.57 vs 36.74 ± 0.98, P < 0.01) expression were markedly increased in ETV-treated group as compared with those in CHB group. The capacity to stimulate proliferation of the allogeneic lymphocytes in ETV-treated group was higher than that in CHB group (1.53 ± 0.09 vs 1.45 ± 0.12, P < 0.05).
CONCLUSION: Entecavir can enhance the biological activity of DC derived from CHB patients and play an indirect antivirus function by regulating the host's immune system.
Collapse
|
48
|
Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254:178-216. [PMID: 17383089 PMCID: PMC7126325 DOI: 10.1016/j.canlet.2007.02.002] [Citation(s) in RCA: 220] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2006] [Revised: 02/01/2007] [Accepted: 02/05/2007] [Indexed: 12/26/2022]
Abstract
Oncolytic virotherapy is a promising form of gene therapy for cancer, employing nature’s own agents to find and destroy malignant cells. The purpose of this review is to provide an introduction to this very topical field of research and to point out some of the current observations, insights and ideas circulating in the literature. We have strived to acknowledge as many different oncolytic viruses as possible to give a broader picture of targeting cancer using viruses. Some of the newest additions to the panel of oncolytic viruses include the avian adenovirus, foamy virus, myxoma virus, yaba-like disease virus, echovirus type 1, bovine herpesvirus 4, Saimiri virus, feline panleukopenia virus, Sendai virus and the non-human coronaviruses. Although promising, virotherapy still faces many obstacles that need to be addressed, including the emergence of virus-resistant tumor cells.
Collapse
Affiliation(s)
- Markus J.V. Vähä-Koskela
- Åbo Akademi University, Department of Biochemistry and Pharmacy and Turku Immunology Centre, Turku, Finland
- Turku Graduate School of Biomedical Sciences, Turku, Finland
- Corresponding author. Address: Åbo Akademi University, Department of Biochemistry and Pharmacy and Turku Immunology Centre, Turku, Finland. Tel.: +358 2 215 4018; fax: +358 2 215 4745.
| | - Jari E. Heikkilä
- Åbo Akademi University, Department of Biochemistry and Pharmacy and Turku Immunology Centre, Turku, Finland
| | - Ari E. Hinkkanen
- Åbo Akademi University, Department of Biochemistry and Pharmacy and Turku Immunology Centre, Turku, Finland
| |
Collapse
|
49
|
Aguilera Guirao A, Romero Yuste S, Regueiro BJ. [Epidemiology and clinical manifestations of viral hepatitis]. Enferm Infecc Microbiol Clin 2006; 24:264-76. [PMID: 16725087 DOI: 10.1016/s0213-005x(06)73773-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Viral hepatitis is an infectious disease affecting the liver. At this time, five different human hepatitis viruses are recognized and characterized in detail: Hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV). The hepatitis viruses differ widely in their modes of transmission and clinical features. Whereas all of them can cause acute hepatitis, only HBV, HDV, and HCV cause chronic hepatitis. This article reviews the epidemiology and clinical manifestations of the different types of viral hepatitis.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Child
- Child, Preschool
- Female
- Global Health
- Hepatitis Viruses/classification
- Hepatitis Viruses/isolation & purification
- Hepatitis Viruses/physiology
- Hepatitis, Viral, Human/classification
- Hepatitis, Viral, Human/diagnosis
- Hepatitis, Viral, Human/epidemiology
- Hepatitis, Viral, Human/immunology
- Hepatitis, Viral, Human/prevention & control
- Hepatitis, Viral, Human/transmission
- Hepatitis, Viral, Human/virology
- Humans
- Infant
- Male
- Middle Aged
- Viral Hepatitis Vaccines
Collapse
Affiliation(s)
- Antonio Aguilera Guirao
- Microbiología, Complejo Hospitalario Universitario de Santiago de Compostela, Choupana s/n, 15706 Santiago de Compostela, Spain
| | | | | |
Collapse
|
50
|
Bardiya N. Expression in and purification of Hepatitis B surface antigen (S-protein) from methylotrophic yeast Pichia pastoris. Anaerobe 2006; 12:194-203. [PMID: 16931065 DOI: 10.1016/j.anaerobe.2006.05.002] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2005] [Revised: 05/19/2006] [Accepted: 05/22/2006] [Indexed: 11/30/2022]
Abstract
The study describes expression and purification of recombinant hepatitis B small surface antigen (rHBsAg hereafter) in methylotrophic yeast Pichia pastoris strain GS115. For expression of the rHBsAg, a single copy of 678 bp cDNA was inserted at the unique EcoRI site downstream of the alcohol oxidase (AOX 1) promoter of the 8.2 kb pHIL-D2 vector. The cDNA-pHIL-D2 construct was used to transform the strain GS115, resulting in a Mut(S) (Methanol Utilizing Slow) phenotype in which the 226 amino acids containing active and full-length rHBsAg protein could be expressed intra-cellularly during slow growth and induction with methanol. The recombinant protein from the Mut(S) expressor was harvested by cell disruption, and purified first by adsorption-desorption on aerosil followed by two-step chromatographic separation i.e. anion exchange on DEAE resin followed by gel permeation on Superdex 75. Reversed passive hem-agglutination assay (RPHA) was used to test the antigenicity while SDS-PAGE was performed to check the purity of the 27 kDa rHBsAg and its aggregates. The results showed that disruption at 12 Kpsi (three cycles), or 30 Kpsi (1 cycle), desorption with 10mM carbonate buffer (pH 9-10), and storage at 4 degrees C without detergent did not adversely affect the antigenicity of the rHbsAg. However, the presence of detergents such as TritonX100 and deoxycholate in the disruption and desorption buffers, respectively resulted in reduced antigenicity during storage both at 4 and -20 degrees C in spite of higher initial yields.
Collapse
Affiliation(s)
- Nirmala Bardiya
- Center for Advanced Bioseparation Technology Laboratory, Inha University, 253 Yong Hyun Dong, Nam Ku, Inchon-402751, Republic of South Korea.
| |
Collapse
|